Pharma Perspectives Panel Discussion: Successfully Engaging with Large Pharma Companies to Secure Future Partnerships for GBM Therapeutic Development
- Identifying specific data packages, preclinical models and clinical milestones that will make a GBM asset attractive for a partnership, beyond scientific novelty
- Strategies for pitching, due diligence considerations and building collaborative relationships to effectively engage with big pharma business development teams to secure a deal
- Insights into creative deal terms, IP considerations and defining clear roles and responsibilities to ensure both partners are aligned on the path to clinical and commercial success